190898-64-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(4-chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its unique structural properties allow it to be a valuable component in the development of new medications.
Used in Agrochemical Production:
In the agrochemical industry, 2-(4-chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane is utilized as an intermediate in the synthesis of pesticides. Its chemical structure can be manipulated to create compounds with pesticidal properties, contributing to the development of effective crop protection agents.
Used in Organic Synthesis:
2-(4-chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane is employed as a building block in organic synthesis, where its dioxolane ring and substituents can be further modified to create a variety of organic compounds for different applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(4-chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane is used as a starting material for the development of new drugs. Its structural features may provide a foundation for designing molecules with specific biological activities, potentially leading to the creation of novel therapeutic agents.
Potential Biological Activity:
While further research is needed, 2-(4-chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane may exhibit biological activity, which could be harnessed for the development of new drugs or pesticides. Its unique structure may interact with biological targets, offering new avenues for therapeutic intervention.

Upstream product

• 7497-60-1 (4-Chlorophenyl)(4-nitrophenyl)methanone 
• 107-21-1 ethylene glycol 
• 104-15-4 toluene-4-sulfonic acid 
• 6192-52-5 p-toluenesulfonic acid monohydrate 
• 108-90-7 chlorobenzene 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 190898-77-2 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2,1-benzisoxazole 
• 501421-81-4 (R,S)-6-[(4-chlorophenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-(3-hydroxy-3-methylbutyn-1-yl)-phenyl)-1-methyl-1H-quinolin-2-one 
• 439153-64-7 6-[(4-chlorophenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one 
• 501421-82-5 6-(4-chlorobenzoyl)-4-(3-bromo-phenyl)-1-methyl-1H-quinolin-2-one 
• 439906-67-9 4-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-benzenamine 
• 190898-65-8 5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-3-(3-methoxyphenyl)-2,1-benzisoxazole 
• 432553-06-5 2-bromo-N-[2-[(3-chlorophenyl)hydroxymethyl]4-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]phenyl]-acetamide 
• 215034-80-3 2,2,2-trichloro-N-{2-(3-chloro-benzoyl)-4-[2-(4-chloro-phenyl)-[1,3]dioxolan-2-yl]-phenyl}-acetamide 
• 432552-78-8 5-(3-chlorophenyl)-7-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,5-dihydro-4,1-benzothiazepin-2(3H)-one 
• 432552-79-9 5-(3-chlorophenyl)-7-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-1,5-dihydro-1-methyl-4,1-benzoxazepin-2(3H)-one 

Relevant academic research and scientific papers

Synthesis Routes Towards the Farnesyl Protein Transferase Inhibitor ZARNESTRA

The discovery that post-translational farnesylation of Ras oncoprotein was an essential step in exercising its biological effect led to the design of farnesyl protein transferase inhibitors (FTIs) in order to control growth of tumors bearing Ras mutations. Pre-clinical studies on murine models have confirmed their inhibitory effect on tumor growth and enabled clinical development. R115777 (ZARNESTRA) is currently undergoing clinical evaluation and recent studies have confirmed its antitumor potential and low toxicity. We wish to describe here the chemical synthesis routes that our group have developed to access ZARNESTRA. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.

Streamlined processes for the synthesis of a farnesyl transferase inhibitor drug candidate

As part of a fast-paced oncology program, quinolinone 1 was discovered and developed as a potent inhibitor of farnesyl transferase for the treatment of cancer. The initial synthesis, which suffered from a lengthy linear sequence and a late-stage chromatog

5-Imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors

The evaluation of structure-activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described.

(Imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation

This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyul, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(=))—R9or —Alk1—S(O)2—R9; R2, R3and R16each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1Ar2C1-6alkyl, Ar2-oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4and R5each independently are hydrogen, halo, Ar1, C1-6-alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbony, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkul or C1-6alkylS(O)2C1-6alkyl; R6and R7independenly are hydrogen, halo, cyano, C1-6alkyl, 4,4-dimethyl-oxazolyl, C1-6alkyloxy or Ar2oxyl R8is hydrogen, C1-6alkyl, cyano, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylC1-6alkyl, cyanoC1-6alkyl, C1-6alkyloxycarbonylC1-6alkyl, carboxyC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, imidazolyl, haloC1-6alkyl, C1-6alkyloxyC1-6alkyl, aminocarbonylC1-6alkyl, or a radical of formula —O—R10, —S—R10, —N—R11R12; R17is hydrogen, halo, cyano, C1-6alkyl, C106alkyloxycarbonyl, Ar1; R18is hydrogen, C1-6alkyl, C1-6alkyloxy or halo; R19is hydrogen or C1-6alkyl; for the manufacture of a medicament to inhibit smooth muscle cell proliferation.

Farnesyltransferase inhibiting quinazolinones

This invention concerns compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1and R2eac

Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives

PCT No. PCT/EP96/04515 Sec. 371 Date May 26, 1998 Sec. 102(e) Date May 26, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/21701 PCT Pub. Date Jun. 19, 1997This invention comprises the novel compounds of formula (I) wherein the dotted line represents an op